Abstract
The effect of sodium-glucose cotransporter 2 inhibitors on peripheral nerves and kidneys in diabetes mellitus (DM) remains unexplored. Therefore, this study aimed to explore the effect of empagliflozin in diabetic rats. DM in rats was induced by streptozotocin injection, and diabetic rats were treated with empagliflozin 3 or 10 mg/kg. Following 24-week treatment, response thresholds to four different stimuli were tested and found to be lower in diabetic rats than in normal rats. Empagliflozin significantly prevented hypersensitivity (P < 0.05) and the loss of skin intraepidermal nerve fibers, and mesangial matrix expansion in diabetic rats. Results of this study demonstrate the potential therapeutic effects of empagliflozin for the treatment of diabetic peripheral neuropathy and nephropathy.
| Original language | English |
|---|---|
| Pages (from-to) | 338-342 |
| Number of pages | 5 |
| Journal | Diabetes and Metabolism Journal |
| Volume | 42 |
| Issue number | 4 |
| DOIs | |
| State | Published - 2018.08.1 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Diabetes mellitus
- Diabetic nephropathies
- Diabetic neuropathies
- Experimental
- Peripheral nerves
- Sodium-glucose transporter 2
Quacquarelli Symonds(QS) Subject Topics
- Medicine
Fingerprint
Dive into the research topics of 'Effect of empagliflozin, a selective sodium-glucose cotransporter 2 inhibitor, on kidney and peripheral nerves in streptozotocin-induced diabetic rats'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver